艾迪注射液辅助肝动脉栓塞化疗治疗原发性肝癌的临床疗效  

Clinical Efficacy of Addie Injection Combined with Transcatheter Arterial Chemoembolization in the Treatment of Primary Liver Cancer

作　　者：魏洪波 崔颖[1] 甄威 李鹏艳 吴冰 WEI Hongbo;CUI Ying;ZHEN Wei;LI Pengyan;WU Bing(Research Institute of Liaoning Province Traditional Chinese Medicine Research/The Second Affiliated Hospital of LiaoningUniversity of Traditional Chinese Medicine,Shenyang,Liaoning,110000,China)

机构地区：[1]辽宁省中医药研究院/辽宁省中医药大学附属第二医院,辽宁沈阳110000

出　　处：《肿瘤药学》2018年第5期743-747,共5页Anti-Tumor Pharmacy

摘　　要：目的探讨原发性肝癌采用肝动脉栓塞化疗(TACE)治疗后,辅用艾迪注射液的临床疗效。方法选取确诊的中晚期原发性肝癌84例,随机分为实验组和对照组,各42例。两组患者均采用TACE治疗,实验组在此基础上加用艾迪注射液辅助治疗,比较两组患者的临床疗效、生存率、免疫功能及化疗不良反应。结果治疗后,实验组的客观缓解率为81.0%,对照组为66.7%,差异有统计学意义(P<0.05);实验组6个月、1年、2年生存率分别为90.5%、64.3%、26.2%,对照组分别为83.3%、47.6%、16.7%,差异均有统计学意义(P<0.05);实验组患者的生活质量较对照组显著提高(P<0.05);实验组患者免疫功能较治疗前明显增强(P<0.05),而对照组的免疫功能与治疗前无显著差异(P>0.05),两组患者血清AFP水平均较治疗前显著下降(P<0.05),且实验组显著低于对照组(P<0.05);实验组化疗不良反应的发生率显著高于对照组(P<0.05)。结论艾迪注射液辅助TACE可明显提高中晚期HCC患者近期疗效及生存质量。Objective To investigate the clinical efficacy of Addie injection in the transcatheter arterial chemoembolization(TACE)treatment of primary liver cancer.Methods Eighty-four cases of middle-advanced hepatocellular carcinoma were diagnosed and randomly divided into experimental group(n=42)and control group(n=42).Patients in both groups got TACE treatment.Patients in the experimental group were added with Addie injection adjuvant therapy.After treatment,the clinical efficacy,survival rate,immune ability of patients and the side effects of chemotherapy were compared between the two groups.Results After treatment,the experimental group achieved an objective response rate of 81%,but the control group got the rate of only 66.7%.There was statistical difference between the two groups(P<0.05).As for the halfyear,1-year and 2-year survival rate,it was 90.5%,64.3% and 26.2% respectively in the experimental group,and 83.3%,47.6% and 16.7% respectively in the control group; the differences were statistically significant between the two groups(P<0.05).The quality of life of patients in the experimental group was significantly better than in the control group(P<0.05).Compared with before treatment,patients in the experimental group had their immune ability enhanced greatly(P<0.05),but no obvious changes in immunity were observed in the control group after treatment(P>0.05).The AFP level decreased in both groups when compared with before treatment(P<0.05),and it was significantly lower in the experimental group than in the control group after treatment(P<0.05).During chemotherapy,the incidence rate of adverse reactions in the experimental group was higher than in the control group(P<0.05).Conclusion Addie injection adjuvant therapy could improve the clinical efficacy and quality of life in the TACE treatment of patients with middle-advanced HCC.

关 键 词：原发性肝癌 艾迪注射液 TACE 免疫功能 疗效 

分 类 号：R735.7[医药卫生—肿瘤]